Tarsus Pharmaceuticals (TARS) Gross Profit (2021 - 2026)

Tarsus Pharmaceuticals' Gross Profit history runs 6 years deep, the most recent figure standing at $152.7 million for Q1 2026.

• In Q1 2026, Gross Profit rose 108.77% year-over-year to $152.7 million; the TTM figure through Mar 2026 stood at $500.2 million (up 130.2% YoY), while the FY2025 annual figure was $420.7 million, up 147.27% from the prior year.
• Gross Profit for Q1 2026 stood at $152.7 million, up from $140.7 million in the prior quarter.
• The five-year high for Gross Profit was $152.7 million in Q1 2026, with the low at $506000.0 in Q1 2022.
• The 5-year median for Gross Profit is $37.8 million (2024), against an average of $52.3 million.
• The sharpest annual moves came in 2022 and 2024: Gross Profit sank 98.43% in 2022, then soared 2903.75% in 2024.
• Tarsus Pharmaceuticals' Gross Profit stood at $9.6 million in 2022, then rose by 23.54% to $11.9 million in 2023, then surged by 418.4% to $61.5 million in 2024, then soared by 128.91% to $140.7 million in 2025, then increased by 8.47% to $152.7 million in 2026.
• Business Quant data shows TARS's Gross Profit at $152.7 million in Q1 2026, $140.7 million in Q4 2025, and $110.4 million in Q3 2025.